Oct 2026· International Journal of Molecular Sciences· Vol 27 21, pp. 9633· 0 citations· 31 references
Medicine
TL;DR
Compact tumor-agnostic plasma sequencing provides complementary molecular information, but its clinical utility requires further validation.
Abstract
Plasma circulating tumor DNA (ctDNA) profiling may complement tissue hotspot testing and reveal molecular changes during treatment of metastatic colorectal cancer (mCRC). We prospectively studied 39 patients with newly diagnosed unresectable mCRC receiving first-line therapy. Cell-free DNA was collected before treatment and after two and four cycles and analyzed using a 10 kb, 10-gene hybrid-capture sequencing panel with molecular barcodes and error correction. Baseline oncogenic variants were detected in 32 of 35 evaluable patients (91.4%). Compared with routine tissue PCR for shared RAS/BRAF targets, plasma testing showed 84.2% sensitivity (16/19) and 100% specificity (19/19) in the intention-to-test cohort, compared with 88.2% sensitivity (15/17) and 100% specificity (17/17) among technically evaluable samples. Three activating KRAS variants (L19F, A59T, and A146T) lay outside the tissue assays' target regions; patients carrying these alterations received anti-EGFR therapy. Patients with metastases in two or more organs had more detectable oncogenic alterations than those with one metastatic site (median, three versus two; adjusted q = 0.00184; rank-biserial correlation = 0.687). Serial sampling revealed divergent trajectories of individual variants in nine patients. Early reductions in plasma variant allele frequencies tended to be greater among partial responders, although associations with radiological response were not significant after multiple testing correction. Compact tumor-agnostic plasma sequencing provides complementary molecular information, but its clinical utility requires further validation.
Circulating tumor DNA (ctDNA) profiling can complement tissue testing in advanced non-small-cell lung cancer (NSCLC), particularly when tissue is unavailable or unable to capture tumor heterogeneity. We evaluated the analytical and clinical performance of Illumina Solid Tumor Panel 80 (IST80 Plus), a focused hybrid-cap...
P. Mediavilla-Medel, R. Serna-Blasco, Lucía Robado de Lope et al.· The journal of liquid biopsy· 0 citations
Background: Comprehensive molecular profiling is increasingly important in advanced non-small cell lung cancer (NSCLC), but the integration of tissue- and plasma-based next-generation sequencing (NGS) and its real-world therapeutic impact remain uncertain. Methods: We conducted a retrospective single-center study of 20...
Ana Gómez Rueda, P. Garrido-López, L. Pekarek et al.· Medical Science· 0 citations
The transition from single-gene testing to comprehensive genomic profiling (CGP) is essential for precision oncology. The next generation sequence platform, enables the simultaneous detection of diverse variants and complex immuno-oncology biomarkers, providing a holistic view of the tumor genomic landscape....
Chung-Gue Huang, Shu-Li Yang, Chang-Fu Kuo et al.· Clinical Chemistry· 0 citations
Abstract Background Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera Genome, a whole-genome sequencing (WGS)-based ctDNA assay, in a diverse pan-...
Mridula A. George, Gary S. Schwartz, W. McHayleh et al.· The Oncologist· 0 citations
Plasma-based NGS identifies clinically relevant genomic alterations in metastatic lung adenocarcinoma and complementstissue-based molecular testing in routine practice in a real-world setting.
E. Kocaaslan, Emir Göçer, Fırat Akagündüz et al.· Marmara Medical Journal· 0 citations
PURPOSE
COPE evaluated serial circulating tumor DNA (ctDNA) profiling with molecular tumor board (MTB) review during first-line therapy for advanced non-small cell lung cancer (NSCLC).
EXPERIMENTAL DESIGN
COPE was a multicenter, randomized (2:1), noncomparative phase II trial. Arm A underwent serial plasma profiling...
Candice Francheska B. Tambaoan, Letuan Phan, S. Cousin et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.